Get the Stockscreener App
4.68
0.64%
-0.03
Pre-market:
4.58
-0.10
-2.14%
Intensity Therapeutics Inc stock is traded at $4.68, with a volume of 19,424.
It is down -0.64% in the last 24 hours and down -10.86% over the past month.
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
See More
Previous Close:
$4.71
Open:
$4.71
24h Volume:
19,424
Relative Volume:
0.57
Market Cap:
$12.65M
Revenue:
-
Net Income/Loss:
$-11.61M
P/E Ratio:
-0.738
EPS:
-6.3418
Net Cash Flow:
$-9.23M
1W Performance:
+1.96%
1M Performance:
-10.86%
6M Performance:
-52.76%
1Y Performance:
-41.08%
1-Day Range:
$4.60
$4.76
1-Week Range:
$4.53
$4.77
52-Week Range:
$4.50
$43.50
Intensity Therapeutics Inc Stock (INTS) Company Profile
Name
Intensity Therapeutics Inc
Sector
Industry
Phone
203-221-7381
Address
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Compare INTS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
4.68 | 12.73M | 0 | -11.61M | -9.23M | -6.3418 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Intensity Therapeutics Inc Stock (INTS) Latest News
Intensity Therapeutics Inc. (INTS) upgraded to buy: Here's what you should know - MSN
INTS Technical Analysis | Trend, Signals & Chart Patterns | INTENSITY THERAPEUTICS INC (NASDAQ:INTS) - ChartMill
INTS Stock Price, Quote & Chart | INTENSITY THERAPEUTICS INC (NASDAQ:INTS) - ChartMill
Benchmark reiterates Intensity Therapeutics stock rating on clinical progress By Investing.com - Investing.com South Africa
Benchmark reiterates Intensity Therapeutics stock rating on clinical progress - Investing.com India
INTS News | INTENSITY THERAPEUTICS INC (NASDAQ:INTS) - ChartMill
Intensity Therapeutics shares plunge 30% after $4 million discounted stock offering - MSN
Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award - ChartMill
Intensity Therapeutics Inc. (INTS) could find a support soon, here's why you should buy the stock now - MSN
How Intensity (INTS) maintains its competitive edge | Q4 2025: Earnings UnderperformMomentum Pick - Newser
A. G. P. Maintains Intensity Therapeutics(INTS.US) With Buy Rating, Maintains Target Price $30 - Moomoo
How Intensity (INTS) talent strategy drives results | Q1 2026: Profit Exceeds ViewsEarnings Acceleration Picks - Newser
Intensity Therapeutics (NASDAQ:INTS) Q1 2026 Results Show EPS Beat Despite No Revenue - ChartMill
8-K: Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updatemoomoo - Moomoo
Trial updates frame Intensity Therapeutics (NASDAQ: INTS) Q1 2026 loss - Stock Titan
Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - Barchart.com
Intensity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
INTENSITY THERAPEUTICS ($INTS) Releases Q1 2026 Earnings - Quiver Quantitative
INTS Q1'26 Earnings: EPS estimate is (1.08) USD - TradingView
Why Intensity (INTS) ability to execute stands out (Slow Grind) 2026-05-05Top Analyst Picks - newser.com
Intensity Therapeutics (INTS) price target decreased by 12.76% to 49.98 - MSN
Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance Singapore
Intensity Therapeutics (INTS) proxy adds equity plan shares, sets 2026 virtual vote - Stock Titan
[ARS] INTENSITY THERAPEUTICS, INC. SEC Filing - Stock Titan
Intensity Therapeutics (INTS) price target decreased by 11.32% to 57.29 - MSN
Why Is Retail Going Gaga Over INTS Stocks Today? - MSN
Intensity Therapeutics announces pricing of $4M registered direct offering of common stock - MSN
Intensity Therapeutics (INTS) Institutional Ownership 2026 $INTS - MarketBeat
Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update - Aktiellt
Why Did INTS Stock Plummet 25% Today? - Dailyhunt
Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation - ADVFN
Intensity (INTS) Stock: Market Pricing (Drifts Lower) 2026-04-15Large Cap Trends - The Legal Advocate
Support Test: Can Intensity Therapeutics Inc disrupt its industryGap Down & Long-Term Safe Investment Ideas - baoquankhu1.vn
Intratumoral Cancer Therapies Market: Expanding Revenue Landscape to 2034 – DelveInsight | Amgen, Daiichi Sankyo, AiViva BioPharma, Lytix Biopharma, Regeneron Pharma, Checkmate Pharma, Replimune - Barchart
Intratumoral Cancer Therapies Market: Expanding Revenue - openPR.com
Update Report: Is Intensity Therapeutics Inc likely to announce a buybackQuarterly Investment Review & Comprehensive Market Scan Reports - baoquankhu1.vn
Aug Technicals: Does Intensity Therapeutics Inc have a competitive edge2026 Trends & Expert Approved Trade Ideas - baoquankhu1.vn
Aug Fed Impact: Can Intensity Therapeutics Inc benefit from deglobalization2026 Price Targets & Scalable Portfolio Growth Methods - baoquankhu1.vn
RSI Check: What are Intensity Therapeutics Incs recent SEC filings showingPortfolio Update Summary & Weekly Sector Rotation Insights - baoquankhu1.vn
Is Intensity (INTS) Stock Good for Passive Investors | Price at $5.49, Down 2.92%Open Stock Picks - Newser
Intensity Therapeutics Inc Stock (INTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):